Cosmos Health (NASDAQ:COSM – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.
Insider and Institutional Ownership
12.6% of Cosmos Health shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 25.1% of Cosmos Health shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Cosmos Health and Xenetic Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cosmos Health | 1 | 0 | 0 | 0 | 1.00 |
| Xenetic Biosciences | 1 | 1 | 0 | 0 | 1.50 |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cosmos Health | $54.43 million | 0.28 | -$16.18 million | ($0.75) | -0.59 |
| Xenetic Biosciences | $2.50 million | 2.24 | -$3.96 million | ($2.05) | -1.19 |
Xenetic Biosciences has lower revenue, but higher earnings than Cosmos Health. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cosmos Health and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cosmos Health | -31.01% | -33.19% | -13.65% |
| Xenetic Biosciences | -110.42% | -64.66% | -54.63% |
Volatility and Risk
Cosmos Health has a beta of 5.34, indicating that its stock price is 434% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500.
Summary
Cosmos Health beats Xenetic Biosciences on 8 of the 12 factors compared between the two stocks.
About Cosmos Health
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
